Amerikanische Gesellschaft für Hirudotherapie

Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children.

Review published in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG (2015)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungBuck · The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2015

Abstract

Bivalirudin, a direct thrombin inhibitor, is a useful alternative to heparin for anticoagulation in infants and children. It has been found to be effective in patients requiring treatment of thrombosis, as well as those needing anticoagulation during cardiopulmonary bypass, extracorporeal life support, or with a ventricular assist device. While it has traditionally been used in patients who were unresponsive to heparin or who developed heparin-induced thrombocytopenia, it has recently been studied as a first-line agent. Bivalirudin, unlike heparin, does not require antithrombin to be effective, and as a result, has the potential to provide a more consistent anticoagulation. The case reports and clinical studies currently available suggest that bivalirudin is as effective as heparin at reaching target activated clotting times or activated partial thromboplastin times, with equivalent or the lower rates of bleeding or thromboembolic complications. It is more expensive than heparin, but the cost may be offset by reductions in the costs associated with heparin use, including anti-factor Xa testing and the need for administration of antithrombin. The most significant disadvantage of bivalirudin remains the lack of larger prospective studies demonstrating its efficacy and safety in the pediatric population.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Zusammenfassung

Bivalirudin, a direct thrombin inhibitor, is a useful alternative to heparin for anticoagulation in infants and children. It has been found to be effective in patients requiring treatment of thrombosis, as well as those needing anticoagulation during cardiopulmonary bypass, extracorporeal life...

Warum dies für die Hirudotherapie relevant ist

This review examines bivalirudin, described in the abstract as a direct thrombin inhibitor and useful alternative to heparin for anticoagulation in infants and children, including in thrombosis treatment, cardiopulmonary bypass, extracorporeal life support, and ventricular assist devices. Bivalirudin does not require antithrombin as a cofactor, potentially offering more consistent anticoagulation than heparin, and available case reports and clinical studies suggest comparable or favorable efficacy and safety, though larger prospective pediatric studies are lacking. The abstract makes no mention of leeches, hirudotherapy, hirudin, or any leech-derived origin for bivalirudin. Any relevance to ASH's domain is limited to the shared mechanistic class of direct thrombin inhibition, not to leech therapy or the leech secretome.

Zitation

Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children.

Buck · The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2015

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.